137 related articles for article (PubMed ID: 9033862)
1. [Painful acute liver involvement related to ingestion of fenofibrate].
Rouhier ML; Rifflet H; Rifflet I; Oberti F; Vuillemin E; Chevailler A; Calès P
Gastroenterol Clin Biol; 1996; 20(12):1137-8. PubMed ID: 9033862
[No Abstract] [Full Text] [Related]
2. [Acute cytolytic and cholestatic hepatitis induced by fenofibrate].
Pichon N; Vincensini JF; Rozière A; Labrousse F; Sautereau D; Pillegand B
Gastroenterol Clin Biol; 2003 Oct; 27(10):947-9. PubMed ID: 14631314
[No Abstract] [Full Text] [Related]
3. Acute cholestatic hepatitis induced by fenofibrate.
Hajdu D; Aiglová K; Vinklerová I; Urbánek K
J Clin Pharm Ther; 2009 Oct; 34(5):599-602. PubMed ID: 19744016
[TBL] [Abstract][Full Text] [Related]
4. [Hepatitis caused by fenofibrate].
Massen H; Furet Y
Cah Anesthesiol; 1986 May; 34(3):249-50. PubMed ID: 3742311
[No Abstract] [Full Text] [Related]
5. [Acute hepatitis and drug dermatitis due to fenofibrate (Secalip)].
Fartoux-Heymann L; Narcy-Lambare B; Labayle D; Fischer D
Ann Med Interne (Paris); 2001 Sep; 152(5):353-4. PubMed ID: 11593148
[No Abstract] [Full Text] [Related]
6. [Hepatitis induced by fibrates].
Tudesq N; Bentournes M
Ann Biol Clin (Paris); 2006; 64(5):515-6. PubMed ID: 17124754
[No Abstract] [Full Text] [Related]
7. Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database.
Ma S; Liu S; Wang Q; Chen L; Yang P; Sun H
J Clin Pharm Ther; 2020 Feb; 45(1):204-207. PubMed ID: 31518450
[TBL] [Abstract][Full Text] [Related]
8. Fenofibrate-induced acute cholestatic hepatitis.
Ho CY; Kuo TH; Chen TS; Tsay SH; Chang FY; Lee SD
J Chin Med Assoc; 2004 May; 67(5):245-7. PubMed ID: 15357112
[TBL] [Abstract][Full Text] [Related]
9. Risk of adverse events with fibrates.
Alsheikh-Ali AA; Kuvin JT; Karas RH
Am J Cardiol; 2004 Oct; 94(7):935-8. PubMed ID: 15464682
[TBL] [Abstract][Full Text] [Related]
10. Identification and Characterization of Fenofibrate-Induced Liver Injury.
Ahmad J; Odin JA; Hayashi PH; Chalasani N; Fontana RJ; Barnhart H; Cirulli ET; Kleiner DE; Hoofnagle JH
Dig Dis Sci; 2017 Dec; 62(12):3596-3604. PubMed ID: 29119413
[TBL] [Abstract][Full Text] [Related]
11. Acute renal failure due to fenofibrate monotherapy.
Usküdar Cansu D; Yaşar NS; Korkmaz C
Anadolu Kardiyol Derg; 2011 Jun; 11(4):371-2. PubMed ID: 21592934
[No Abstract] [Full Text] [Related]
12. [Acute hepatitis: an adverse reaction to fenofibrate treatment].
Bravo ML; Azagra R; Aguyé A; Freixas M
Aten Primaria; 1992 Sep; 10(3):697-8. PubMed ID: 1420784
[No Abstract] [Full Text] [Related]
13. [Studies on the risk factors for fenofibrate-induced elevation of liver function tests].
Hayakawa T; Hayashi A; Miyakawa M; Shimoyama K; Sekiya S; Sekiguchi M; Inotsume N
Yakugaku Zasshi; 2002 Feb; 122(2):169-75. PubMed ID: 11857958
[TBL] [Abstract][Full Text] [Related]
14. [Chronic active hepatitis associated with antinuclear antibodies induced by fenofibrate].
Bernard PH; Lamouliatte H; Le Bail B; Bioulac-Sage P; Quinton A; Balabaud C
Gastroenterol Clin Biol; 1994; 18(11):1048-9. PubMed ID: 7705574
[No Abstract] [Full Text] [Related]
15. [Acute severe fibrosing hepatitis associated with ciprofibrate treatment].
Dumortier J; Slim R; Chevallier M; Boillot O; Thaunat JL; Vaillant E; Vial T; Bellemin B; Paliard P; Scoazec JY
Gastroenterol Clin Biol; 1999 Dec; 23(12):1399-400. PubMed ID: 10642628
[No Abstract] [Full Text] [Related]
16. [Drug-induced hepatitis due to fenofibrate].
Couzigou P; Boutillier P; Boisseau C; Faucher P; De Mascarel A; Amouretti M; Beraud C; Boisseau A; Dangoumau J
Therapie; 1980; 35(3):403. PubMed ID: 7423433
[No Abstract] [Full Text] [Related]
17. Fenofibrate-induced cirrhosis.
Ahmed F; Petrovic L; Rosen E; Gonzalez R; Jacobson IM
Dig Dis Sci; 2005 Feb; 50(2):312-3. PubMed ID: 15745090
[No Abstract] [Full Text] [Related]
18. Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism.
Clouâtre Y; Leblanc M; Ouimet D; Pichette V
Nephrol Dial Transplant; 1999 Apr; 14(4):1047-8. PubMed ID: 10328516
[No Abstract] [Full Text] [Related]
19. A case of rhabdomyolysis complicated with acute renal failure after resumption of fenofibrate therapy: a first report.
Kiskac M; Zorlu M; Cakirca M; Karatoprak C; Peru C; Erkoc R; Yavuz E
Indian J Pharmacol; 2013; 45(3):305-6. PubMed ID: 23833382
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity.
Kostapanos MS; Athyros VG; Mikhailidis DP; Elisaf MS
J Clin Lipidol; 2013; 7(1):88. PubMed ID: 23351588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
